Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.
Lomakin NV, Bakirov BA, Protsenko DN, Mazurov VI, Musaev GH, Moiseeva OM, Pasechnik ES, Popov VV, Smolyarchuk EA, Gordeev IG, Gilyarov MY, Fomina DS, Seleznev AI, Linkova YN, Dokukina EA, Eremeeva AV, Pukhtinskaia PS, Morozova MA, Zinkina-Orikhan AV, Lutckii AA. Lomakin NV, et al. Among authors: zinkina orikhan av. Inflamm Res. 2021 Dec;70(10-12):1233-1246. doi: 10.1007/s00011-021-01507-5. Epub 2021 Sep 29. Inflamm Res. 2021. PMID: 34586459 Free PMC article. Clinical Trial.
[A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations].
Boyko AN, Bosenko LP, Vasilovskiy VV, Volkova LI, Zakharova MN, Kotov SV, Lekomtseva EV, Negrich TI, Parshina EV, Patrusheva OP, Prokopenko SV, Sazonov DV, Timchenko PV, Trinitatskiy YV, Khabirov FA, Khavunka MY, Chichanovskaya LV, Sherman MA, Lin'kova YN, Zinkina-Orikhan AV, Tursunova KB. Boyko AN, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):107-113. doi: 10.17116/jnevro201711722107-113. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28617368 Clinical Trial. Russian.
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.
Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina-Orikhan AV. Puig L, et al. Among authors: zinkina orikhan av. Dermatol Ther (Heidelb). 2021 Aug;11(4):1319-1332. doi: 10.1007/s13555-021-00554-4. Epub 2021 May 31. Dermatol Ther (Heidelb). 2021. PMID: 34060012 Free PMC article.
[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
Boyko AN, Boyko OV, Bakhtiyarova KZ, Gusev EI, Dudin VA, Zaslavsky LG, Malkova NA, Parshina YV, Poverennova IY, Siverceva SA, Totolyan NA, Shchur SG, Fedulov AS, Khabirov FA, Bolsun DD, Zinkina-Orikhan AV, Linkova YN, Chernovskaya TV. Boyko AN, et al. Among authors: zinkina orikhan av. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 35175704 Clinical Trial. Russian.
Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study.
Mazurov VI, Dubinina TV, Erdes S, Lapshina SA, Soroka NF, Kunder EV, Smirnov AV, Eremeeva AV, Zinkina-Orikhan AV, Morozova MA, Gaydukova IZ. Mazurov VI, et al. Among authors: zinkina orikhan av. Clin Exp Rheumatol. 2023 Mar;41(3):718-726. doi: 10.55563/clinexprheumatol/ljpqqe. Epub 2022 Aug 31. Clin Exp Rheumatol. 2023. PMID: 36062743 Clinical Trial.
[The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial].
Kulagin AD, Bakirov BA, Davydkin IL, Elykomov IV, Konstantinova TS, Korobkin AV, Kosinova MV, Mazurov VI, Minaeva NV, Proidakov AV, Ptushkin VV, Shatokhin YV, Lin'kova YN, Zinkina-Orikhan AV, Morozova MA. Kulagin AD, et al. Among authors: zinkina orikhan av. Ter Arkh. 2021 Nov 15;93(11):1340-1348. doi: 10.26442/00403660.2021.11.201226. Ter Arkh. 2021. PMID: 36286657 Clinical Trial. Russian.
[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].
Boyko AN, Bakhtiyarova KZ, Boyko OV, Dudin VA, Zaslavskii LG, Malkova NA, Parshina EV, Poverennova IY, Sivertseva SA, Totolyan NA, Shchur SG, Khabirov FA, Goncharova ZA, Zakharova MN, Bolsun DD, Zinkina-Orikhan AV, Lin'kova YN, Chernovskaya TV, Porozova AA. Boyko AN, et al. Among authors: zinkina orikhan av. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(2):52-59. doi: 10.17116/jnevro202312302152. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 36843459 Clinical Trial. Russian.
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Shchur SG, Artemyeva AV, Bolsun DD, Zinkina-Orikhan AV, Linkova YN. Boyko AN, et al. Among authors: zinkina orikhan av. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(4):37-47. doi: 10.17116/jnevro202312304137. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37084363 Clinical Trial. Russian.
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Bolsun DD, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. Boyko AN, et al. Among authors: zinkina orikhan av. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(7. Vyp. 2):43-52. doi: 10.17116/jnevro202312307243. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37560833 Clinical Trial. Russian.
[Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a].
Boyko AN, Bosenko LP, Vasilovskiy VV, Volkova LI, Zakharova MN, Kotov SV, Lekomtseva EV, Negrich TI, Parshina EV, Patrusheva OP, Prokopenko SV, Sazonov DV, Timchenko LV, Trinitatskiy YV, Khabirov FA, Khavunka MY, Chichanovskaya LV, Sherman MA, Ivanov RA, Lin'kova YN, Stukalina EY, Zinkina-Orikhan AV, Obukhova IG. Boyko AN, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):73-85. doi: 10.17116/jnevro20191192273. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31156245 Clinical Trial. Russian.
13 results